The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.

Provided are compounds of Formula I: ##STR00001## and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

Provided are compounds of Formula I: ##STR00001## and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

Provided are compounds of Formula I: ##STR00001## and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders.

Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders.

The disclosure features methods of treating RAS disorders using safe and effective doses of Compound A, or a pharmaceutically acceptable salt thereof. The disclosure also features methods of treating RAS disorders including combination therapies comprising Compound A, or a pharmaceutically acceptable salt thereof, and additional therapeutic agent. Compound A is a compound having the following structure:

##STR00001##

The disclosure features methods of treating RAS disorders using safe and effective doses of Compound A, or a pharmaceutically acceptable salt thereof. The disclosure also features methods of treating RAS disorders including combination therapies comprising Compound A, or a pharmaceutically acceptable salt thereof, and additional therapeutic agent. Compound A is a compound having the following structure:

##STR00001##

Provided are compounds of Formula I:

##STR00001##

and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.